<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="ccb6c97f-34f9-4aeb-81ba-824a9b8a0ecd"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use METRONIDAZOLE GEL safely and effectively. See full prescribing information for METRONIDAZOLE GEL.<br/>
      <br/>METRONIDAZOLE gel, for topical use<br/>Initial U.S. Approval: 1963<br/>
   </title>
   <effectiveTime value="20250318"/>
   <setId root="e43b880b-ce69-4f56-9c1c-9c7ca23bba84"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="650574663" root="1.3.6.1.4.1.519.1"/>
            <name>Alembic Pharmaceuticals Limited</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="650574663" root="1.3.6.1.4.1.519.1"/>
                  <name>Alembic Pharmaceuticals Limited</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="871411532" root="1.3.6.1.4.1.519.1"/>
                        <name>Alembic Pharmaceuticals Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="46708-630" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="46708-630" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="1e35bce8-b475-4d6a-a3ef-940810a21ebc"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL Product Data Elements Section"/>
               <effectiveTime value="20250318"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="46708-630" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Metronidazole</name>
                        <formCode code="C42934" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GEL"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Metronidazole</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="10" unit="mg"/>
                              <denominator value="1" unit="g"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="140QMO216E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METRONIDAZOLE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="140QMO216E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METRONIDAZOLE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="JV039JZZ3A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BETADEX</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EDETATE DISODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="A2I8C7HI9T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPARABEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="25X51I8RD4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>NIACINAMIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="HIE492ZZ3T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PHENOXYETHANOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Z8IX2SC1OH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLPARABEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ZYD53NBL45" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYETHYL CELLULOSE (4000 MPA.S AT 1%)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="g"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C42794" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TUBE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="46708-630-60" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250317"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="55" unit="g"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43174" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PUMP"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="46708-630-55" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250317"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="45" unit="g"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C42794" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TUBE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="46708-630-45" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250317"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA212646" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250317"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38304" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TOPICAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID1">
               <id root="328d4eba-4d39-41e5-9861-4696f43ae7f8"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph ID="ID2">Metronidazole gel, 1% is nitroimidazole indicated for the topical treatment of inflammatory lesions of rosacea. </paragraph>
               </text>
               <effectiveTime value="20250318"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID69">Metronidazole gel, 1% is a nitroimidazole indicated for the topical treatment of inflammatory lesions of rosacea. (<linkHtml href="#ID1">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID3">
               <id root="af75cb6c-40a7-482e-aa23-a563d458ec18"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <list listType="unordered" ID="ID105" styleCode="Disc">
                     <item>Cleanse treated areas before the application of metronidazole gel.</item>
                     <item>Apply and rub in a thin film of metronidazole gel once daily to affected area(s).</item>
                     <item>Cosmetics may be applied after the application of metronidazole gel.</item>
                     <item>For topical use only, not for oral, ophthalmic, or intravaginal use.</item>
                  </list>
               </text>
               <effectiveTime value="20250318"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID85" styleCode="Disc">
                           <item>Cleanse treated areas before the application of metronidazole gel (<linkHtml href="#ID3">2</linkHtml>)</item>
                           <item>Apply and rub in a thin film of metronidazole gel once daily to affected area(s). (<linkHtml href="#ID3">2</linkHtml>)</item>
                           <item>Cosmetics may be applied after the application of metronidazole gel. (<linkHtml href="#ID3">2</linkHtml>)</item>
                           <item>Not for oral, ophthalmic or intravaginal use. (<linkHtml href="#ID3">2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID5">
               <id root="0f109b51-58cd-47b7-b158-830dbce869aa"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph ID="ID6">Gel, 1%. Metronidazole gel USP is a clear, colorless to pale yellow gel. Each gram of metronidazole gel USP contains 10 mg (1%) of metronidazole USP.</paragraph>
               </text>
               <effectiveTime value="20250318"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID73">Gel, 1%. </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID7">
               <id root="a95457a1-4fe0-429b-8c62-235de68ac90b"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph ID="ID8">Metronidazole gel is contraindicated in patients with a history of hypersensitivity to metronidazole or to any other ingredient in the formulation.</paragraph>
               </text>
               <effectiveTime value="20250318"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID75">Metronidazole gel is contraindicated in those patients with a history of hypersensitivity to metronidazole or to any other ingredient in this formulation. (<linkHtml href="#ID7">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID9">
               <id root="e80ce52c-4d1e-4aac-9b6a-4c0c7d677ad4"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250318"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID84" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Neurologic Disease:</content>Peripheral neuropathy, characterized by numbness      or paresthesia of an extremity has been reported in patients treated with      systemic metronidazole. Peripheral neuropathy has been reported with the      post approval use of topical metronidazole. Immediate      reevaluate Metronidazole gel therapy if abnormal neurologic signs appear.      (<linkHtml href="#ID12">5.1</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Blood Dyscrasias:</content>Metronidazole gel is a nitroimidazole; use with      care in patients with evidence of, or history of, blood dyscrasia. (<linkHtml href="#ID14">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Contact Dermatitis:</content>If dermatitis occurs, patients may need to      discontinue use. (<linkHtml href="#ID16">5.3</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Eye Irritation:</content>Topical metronidazole has been reported to cause      tearing of the eyes. Avoid contact with the eyes. (<linkHtml href="#ID18">5.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID12">
                     <id root="e2bb2c57-8a17-461a-97e0-0f5aab1d759a"/>
                     <title>5.1 Neurologic Disease</title>
                     <text>
                        <paragraph ID="ID13">Peripheral neuropathy, characterized by numbness or paresthesia of an extremity, has been reported in patients treated with systemic metronidazole. peripheral neuropathy has been reported with the post approval use of topical metronidazole. Immediately reevaluate metronidazole gel therapy if abnormal neurologic signs appear. Administer metronidazole with caution to patients with central nervous system diseases.</paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
               <component>
                  <section ID="ID14">
                     <id root="bf9257cb-0006-4b7e-9c2e-f0b0613d0255"/>
                     <title>5.2 Blood Dyscrasias</title>
                     <text>
                        <paragraph ID="ID15">Metronidazole gel is a nitroimidazole; use with care in patients with evidence of, or history of, blood dyscrasia.</paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
               <component>
                  <section ID="ID16">
                     <id root="78484a58-b44f-4b43-b8d8-027659815148"/>
                     <title>5.3 Contact Dermatitis</title>
                     <text>
                        <paragraph ID="ID17">Irritant and allergic contact dermatitis have been reported with metronidazole gel.  If dermatitis occurs, patients may need to discontinue use.</paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
               <component>
                  <section ID="ID18">
                     <id root="3e9d2067-6407-40e3-93c5-97ba0d2126f4"/>
                     <title>5.4 Eye Irritation</title>
                     <text>
                        <paragraph ID="ID19">Topical metronidazole has been reported to cause tearing of the eyes. Avoid contact with the eyes.</paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID20">
               <id root="ec66fb30-5725-4300-bccf-b906e62e884e"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph ID="ID103">The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <paragraph>● Neurologic Disease [see Warnings and Precautions (5.1)]</paragraph>
                  <paragraph>● Contact Dermatitis [see Warnings and Precautions (5.3)]</paragraph>
                  <paragraph>● Eye Irritation [see Warnings and Precautions (5.4)]</paragraph>
               </text>
               <effectiveTime value="20250318"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID22">Most common adverse reactions (incidence &gt; 2%) are nasopharyngitis, upper respiratory tract infection, and headache. (<linkHtml href="#ID20">6</linkHtml>)</paragraph>
                        <paragraph ID="ID86">
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088 or <content styleCode="italics">www.fda.gov/medwatch</content>.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID23">
                     <id root="3bcd5eb9-711c-4264-9490-4b471fbaadbc"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph ID="ID24">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. </paragraph>
                        <paragraph>In a controlled clinical trial, 557 subjects used metronidazole gel, 1% and 189 subjects used the gel vehicle once daily for up to 10 weeks. The following table summarizes selected adverse reactions that occurred at a rate of ≥1% and at a higher rate than vehicle:</paragraph>
                        <table ID="ID25" width="690" styleCode="Noautorules">
                           <caption>   Table 1: Adverse Reactions That Occurred at a Rate of  ≥1% and Higher Than Vehicle in Subjects Treated with metronidazole gel for Up to 10 Weeks </caption>
                           <col width="390"/>
                           <col width="174"/>
                           <col width="126"/>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Preferred Term </content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Metronidazole Gel, 1% </content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Vehicle </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> (N= 557) N (%)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> (N= 189) N (%)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">    Influenza <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 8 (1.4) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1 (0.5) <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">    Upper respiratory tract infection <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 14 (2.5) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 4 (2.1) <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">    Urinary tract infection <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 6 (1.1) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1 (0.5) <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">    Headache <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 12 (2.2) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1 (0.5) <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">    Contact dermatitis <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 7 (1.3) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1 (0.5) <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">    Hypertension <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 6 (1.1) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1 (0.5) <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="ID26" width="678" styleCode="Noautorules">
                           <caption>  Table 2: Local Cutaneous Signs and Symptoms of Irritation That Were Worse Than Baseline in Subjects Treated with metronidazole gel for Up to 10 Weeks </caption>
                           <col width="366"/>
                           <col width="174"/>
                           <col width="138"/>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule"/>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Metronidazole Gel, 1%</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Vehicle </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Sign/Symptom </content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> (N= 544) N (%)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> (N= 184) N (%)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Dryness </content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 138 (25.4) </content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 63 (34.2) </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">   Mild <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 93 (17.1) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 41 (22.3) <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">   Moderate <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 42 (7.7) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 20 (10.9) <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">   Severe <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 3 (0.6) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 2 (1.1) <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Scaling </content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 134 (24.6) </content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 60 (32.6) </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">   Mild <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 88 (16.2) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 32 (17.4) <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">   Moderate <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 43 (7.9) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 27 (14.7) <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">   Severe <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 3 (0.6) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1 (0.5) <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Pruritus </content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 86 (15.8) </content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 35 (19.0) </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">   Mild <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 53 (9.7) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 21 (11.4) <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">   Moderate <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 27 (5.0) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 13 (7.1) <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">   Severe <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 6 (1.1) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1 (0.5) <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Stinging/burning </content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 56 (10.3) </content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 28 (15.2) </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">   Mild <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 39 (7.2) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 18 (9.8) <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">   Moderate <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 7 (1.3) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 9 (4.9) <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">   Severe <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 10 (1.8) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1 (0.5) <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID27">The following additional adverse reactions have been reported with the topical use of metronidazole: transient redness, metallic taste, tingling or numbness of extremities, and nausea.</paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
               <component>
                  <section ID="ID28">
                     <id root="8df58d39-2958-42a4-98f2-559e6af6a679"/>
                     <title>6.2 Post marketing Experience</title>
                     <text>
                        <paragraph ID="ID29">The following adverse reaction has been identified during post-approval use of topical metronidazole. Because this reaction is reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System Disorders:</content> Peripheral neuropathy </paragraph>
                        <paragraph>
                           <content styleCode="italics">Ophthalmic Adverse Reactions:</content> Tearing of the eyes</paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID30">
               <id root="210d781b-4973-4ef0-aa5d-50fb91f92793"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph ID="ID31">Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. Use caution when prescribing for patients who are receiving anticoagulant treatment.</paragraph>
               </text>
               <effectiveTime value="20250318"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID78">Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. Use caution when administering metronidazole gel concomitantly to patients who are receiving anticoagulant treatment. (<linkHtml href="#ID30">7</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID32">
               <id root="b7671512-abea-447d-9d2e-aaf88728deb8"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250318"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID107">Lactation: Breastfeeding not recommended.(<linkHtml href="#ID35">8.2</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID33">
                     <id root="879b2e14-eb45-430f-8f67-7a66348961aa"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph ID="ID34">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Available data have not established an association between metronidazole use during pregnancy and major birth defects, miscarriage or other adverse maternal or fetal outcomes. No fetotoxicity was observed after oral administration of metronidazole in pregnant rats or mice. The available data do not allow the calculation of relevant comparisons between the systemic exposures of metronidazole observed in animal studies to the systemic exposures that would be expected in humans after topical use of metronidazole gel.</paragraph>
                        <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
               <component>
                  <section ID="ID35">
                     <id root="104c523b-4898-4b8b-880d-39ef2f881c35"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph ID="ID36">
                           <content styleCode="italics">Risk Summary</content>
                        </paragraph>
                        <paragraph>It is not known whether metronidazole is present in human milk after topical administration. Published literature reports the presence of metronidazole in human milk after oral administration. There are no data on the effects of metronidazole on milk production. Because of the potential for serious adverse reactions, advise patients that breastfeeding is not recommended during treatment with metronidazole gel.</paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
               <component>
                  <section ID="ID37">
                     <id root="63e593e4-3d4f-4843-b731-3f3187834e15"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph ID="ID38">Safety and effectiveness of metronidazole gel have not been established in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
               <component>
                  <section ID="ID39">
                     <id root="7430d5bf-e2e8-4e6f-8506-5155462cd269"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph ID="ID40">Sixty-six subjects aged 65 years and older were treated with metronidazole gel, 1% in the clinical study. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. </paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID43">
               <id root="fae012e2-1e4c-4b0d-832c-d5f5defb8461"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph ID="ID44">Metronidazole gel USP, 1% is a nitroimidazole for topical use. Metronidazole gel USP, 1% is a clear, colorless to pale yellow, aqueous gel. Each gram contains 10 mg of metronidazole. Chemically, metronidazole is 2-methyl-5-nitro-1 <content styleCode="italics">H</content>-imidazole-1-ethanol. The molecular formula for metronidazole is C<sub>6</sub>H<sub>9</sub>N<sub>3</sub>O<sub>3</sub>. It has the following structural formula:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph ID="ID46">Metronidazole has a molecular weight of 171.16. It is a white to pale yellow crystalline powder. It is slightly soluble in alcohol and has solubility in water of 10 mg/mL at 20˚C. Metronidazole belongs to the nitroimidazole class of compounds.</paragraph>
                  <paragraph>The inactive ingredients are betadex, edetate disodium, hydroxyethyl cellulose, methylparaben, niacinamide, phenoxyethanol, propylene glycol, propylparaben and purified water. </paragraph>
               </text>
               <effectiveTime value="20250318"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ccb6c97f-34f9-4aeb-81ba-824a9b8a0ecd-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID47">
               <id root="b88b3b6d-8c29-46f3-9b8a-a4ef302d6321"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250318"/>
               <component>
                  <section ID="ID48">
                     <id root="226abd39-051b-42e7-a2af-b8a81af27b9d"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="ID49">The mechanism of action of metronidazole in the treatment of rosacea is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
               <component>
                  <section ID="ID50">
                     <id root="3f1ce97a-9b2a-44d2-aea5-e55c4aae91e7"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph ID="ID51">The pharmacodynamics of metronidazole in association with the treatment of rosacea are unknown.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiac Electrophysiology:</content> The effect of metronidazole gel on the QTc interval has not been adequately characterized.</paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
               <component>
                  <section ID="ID52">
                     <id root="0727cefb-870a-498f-81e9-608f3cedafd7"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph ID="ID53">Topical administration of a one-gram dose of metronidazole gel to the face of 13 subjects with moderate to severe rosacea once daily for 7 days resulted in a mean ± SD C<sub>max</sub> of metronidazole of 32 ± 9 ng/mL. The mean ± SD AUC<sub>(0 to 24)</sub> was 595 ± 154 ng*hr/mL. The mean C<sub>max</sub> and AUC<sub>(0 to 24</sub>) are less than 1% of the value reported for a single 250 mg oral dose of metronidazole. The time to maximum plasma concentration (T<sub>max</sub>) was 6<sub> </sub>to 10 hours after topical application. </paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID54">
               <id root="5cd41d34-de25-4d1d-a314-9aed03dd1500"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250318"/>
               <component>
                  <section ID="ID55">
                     <id root="0011cd5c-fa5c-4500-ba03-53b17ae5a84d"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="ID56">Metronidazole has shown evidence of carcinogenic activity in studies involving chronic oral administration in mice and rats, but not in studies involving hamsters.</paragraph>
                        <paragraph>In several long-term studies in mice, oral doses of approximately 225 mg/m<sup>2</sup>/day or greater were associated with an increase in pulmonary tumors and lymphomas. Several long-term oral studies in the rat have shown statistically significant increases in mammary and hepatic tumors at doses &gt;885 mg/m<sup>2</sup>/day.</paragraph>
                        <paragraph>Metronidazole has shown evidence of mutagenic activity in several <content styleCode="italics">in vitro</content> bacterial assay systems. In addition, a dose-related increase in the frequency of micronuclei was observed in mice after intraperitoneal injections. An increase in chromosomal aberrations in peripheral blood lymphocytes was reported in patients with Crohn's disease who were treated with 200 to 1200 mg/day of metronidazole for 1 to 24 months. However, in another study, no increase in chromosomal aberrations in circulating lymphocytes was observed in patients with Crohn's disease treated with the drug for 8 months.</paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID57">
               <id root="f9da1b38-e2aa-49ad-b967-f02192df3539"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph ID="ID58">In a randomized, vehicle-controlled trial, 746 subjects with rosacea were treated with metronidazole gel,1% or vehicle once daily for 10 weeks. Most subjects had a disease severity score of 3 ("moderate") on the 5-point Investigator Global Assessment (IGA) scale, with 8 to 50 inflammatory lesions and no more than two nodules at baseline. The co-primary efficacy endpoints were the percent reduction in inflammatory lesion counts and percentage of subjects with success on IGA, defined as an IGA score of 0 ("clear") or 1 ("almost clear") at Week 10.  </paragraph>
                  <paragraph>The efficacy results are shown in the following table: </paragraph>
                  <table ID="ID61" width="684" styleCode="Noautorules">
                     <caption>  Table 3: Inflammatory Lesion Counts and Global Scores in Subjects with Rosacea at Week 10 in a Clinical Trial </caption>
                     <col width="294"/>
                     <col width="96"/>
                     <col width="120"/>
                     <col width="42"/>
                     <col width="132"/>
                     <tbody>
                        <tr>
                           <td rowspan="2" styleCode="Lrule Toprule Botrule Rrule Rrule"/>
                           <td colspan="2" styleCode=" Toprule Botrule Rrule" align="center"> Metronidazole Gel, 1% <br/>
                           </td>
                           <td colspan="2" styleCode=" Toprule Botrule Rrule" align="center"> Vehicle <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> N <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> Results N (%) <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> N <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> Results N (%) <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="center">
                              <content styleCode="bold"> Inflammatory lesions </content>
                              <br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="center"> 557 <br/>
                           </td>
                           <td styleCode=" Botrule Rrule"/>
                           <td styleCode=" Botrule Rrule" align="center"> 189<br/>
                           </td>
                           <td styleCode=" Botrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="center"> Baseline, mean count <br/>
                           </td>
                           <td styleCode=" Botrule Rrule"/>
                           <td styleCode=" Botrule Rrule" align="center"> 18.3 <br/>
                           </td>
                           <td styleCode=" Botrule Rrule"/>
                           <td styleCode=" Botrule Rrule" align="center"> 18.4 <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="center"> Week-10, mean count <br/>
                           </td>
                           <td styleCode=" Botrule Rrule"/>
                           <td styleCode=" Botrule Rrule" align="center"> 8.9 <br/>
                           </td>
                           <td styleCode=" Botrule Rrule"/>
                           <td styleCode=" Botrule Rrule" align="center"> 12.8 <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="center"> Reduction <br/>
                           </td>
                           <td styleCode=" Botrule Rrule"/>
                           <td styleCode=" Botrule Rrule" align="center"> 9.4 (50.7) <br/>
                           </td>
                           <td styleCode=" Botrule Rrule"/>
                           <td styleCode=" Botrule Rrule" align="center"> 5.6 (32.6) <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="center">
                              <content styleCode="bold"> Investigator Global Assessment </content>
                              <br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="center"> 557 <br/>
                           </td>
                           <td styleCode=" Botrule Rrule"/>
                           <td styleCode=" Botrule Rrule" align="center"> 189 <br/>
                           </td>
                           <td styleCode=" Botrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="center"> Subject clear or almost clear <br/>
                           </td>
                           <td styleCode=" Botrule Rrule"/>
                           <td styleCode=" Botrule Rrule" align="center"> 214 (38.42) <br/>
                           </td>
                           <td styleCode=" Botrule Rrule"/>
                           <td styleCode=" Botrule Rrule" align="center"> 52 (27.51) <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="center"> Subject with no change <br/>
                           </td>
                           <td styleCode=" Botrule Rrule"/>
                           <td styleCode=" Botrule Rrule" align="center"> 159 (28.5) <br/>
                           </td>
                           <td styleCode=" Botrule Rrule"/>
                           <td styleCode=" Botrule Rrule" align="center"> 77 (40.7)<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="ID62">Subjects treated with metronidazole gel, 1% experienced a mean reduction of 9.4 inflammatory lesions in the Week-10 LOCF group, compared to a reduction of 5.6 for those treated with vehicle, or a difference in means of 3.8 lesions.</paragraph>
               </text>
               <effectiveTime value="20250318"/>
            </section>
         </component>
         <component>
            <section ID="ID63">
               <id root="0a832104-e61d-4e05-97ee-f852ac90e255"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph ID="ID106">
                     <content styleCode="underline">How Supplied </content>
                  </paragraph>
                  <paragraph>Metronidazole gel USP, 1% is clear, colorless to pale yellow in color, and supplied as follows:</paragraph>
                  <paragraph>45 gram tube- NDC 46708-630-45</paragraph>
                  <paragraph>60 gram tube- NDC 46708-630-60</paragraph>
                  <paragraph>55 gram pump- NDC 46708-630-55</paragraph>
                  <paragraph>
                     <content styleCode="underline">Storage and Handling</content>
                  </paragraph>
                  <paragraph>Store at 20˚ to 25˚C (68˚ to 77˚F); excursions permitted between 15˚ to 30˚C (59˚ to 86˚F) [see USP controlled room temperature].</paragraph>
               </text>
               <effectiveTime value="20250318"/>
            </section>
         </component>
         <component>
            <section ID="ID65">
               <id root="232de78e-03fb-472e-8d15-4a16604d67c5"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph ID="ID66">Advise the Patient to read the FDA-approved patient labeling (Patient Information).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Administration Instructions </content>
                  </paragraph>
                  <paragraph>Use as directed. Avoid contact with the eyes <content styleCode="italics">[see Warnings and Precautions (5.4)].</content>
                  </paragraph>
                  <paragraph>Cleanse treated areas before the application of metronidazole gel<content styleCode="italics"> [see Dosage and Administration (2)]</content>
                  </paragraph>
                  <paragraph>Advise patients to report any adverse reaction to their healthcare providers.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Neurologic Disease </content>
                  </paragraph>
                  <paragraph>Advise patients to immediately report any abnormal neurologic signs to their healthcare provider <content styleCode="italics">[see Warnings and Precautions (5.1)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>Advise women not to breastfeed during treatment with metronidazole gel <content styleCode="italics">[see Use in Specific Populations (8.2)].</content> <content styleCode="bold"> </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only </content>
                  </paragraph>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Alembic Pharmaceuticals Limited</content>
                  </paragraph>
                  <paragraph>(Derma Division),</paragraph>
                  <paragraph>Karakhadi, Vadodara 391450, India.</paragraph>
                  <paragraph>Mfg. License No.: G/25/2216</paragraph>
               </text>
               <effectiveTime value="20250318"/>
            </section>
         </component>
         <component>
            <section ID="ID89">
               <id root="296a39b7-3a8c-4ea4-ba38-0fe645f5e73b"/>
               <code code="68498-5" codeSystem="2.16.840.1.113883.6.1" displayName="PATIENT MEDICATION INFORMATION SECTION"/>
               <title>PATIENT INFORMATION</title>
               <text>
                  <table ID="ID95" width="718" styleCode="Noautorules">
                     <col width="718"/>
                     <tbody>
                        <tr>
                           <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left">
                              <content styleCode="bold">                                                              PATIENT INFORMATION  </content>
                              <br/>
                              <content styleCode="bold">                                                        Metronidazole (MET-roe-NYE-da-zole) Gel, USP 1%</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> Important: Metronidazole gel</content>
                              <content styleCode="bold">  is for use on the skin only (topical use).</content>  Do not use metronidazole gel in your mouth, eyes, or vagina.  <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> What is Metronidazole gel</content>
                              <content styleCode="bold"> ? </content>
                              <br/> Metronidazole gel is a prescription medicine used on the skin (topical) to treat pimples and bumps (inflammatory lesions) caused by a condition called rosacea. <br/>  It is not known if metronidazole gel is safe and effective in children.           <content styleCode="bold">  </content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> Do not use Metronidazole gel</content>
                              <content styleCode="bold">  if </content> you are allergic to metronidazole or any of the ingredients in metronidazole gel. See the end of this leaflet for a complete list of ingredients in metronidazole gel.  <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> Before using Metronidazole gel</content>
                              <content styleCode="bold"> , tell your healthcare provider about all your medical conditions, including if you: </content>
                              <br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>have tingling or numbness in your hands or feet  </item>
                                 <item>have or have had a blood disorder or disease  </item>
                                 <item>are pregnant or plan to become pregnant. It is not known if metronidazole gel will harm your unborn baby. </item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if metronidazole gel passes into your breast milk. Do not breastfeed during treatment with metronidazole gel. Talk to your healthcare provider about the best way to feed your baby during treatment with metronidazole gel. </item>
                              </list>
                              <content styleCode="bold"> Tell your healthcare provider about all of the medicines you take</content> , including prescription and over-the-counter medicines, vitamins, and herbal supplements. <br/> Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.  <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> How should I use Metronidazole gel</content>
                              <content styleCode="bold"> ? </content>
                              <br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>Use metronidazole gel exactly as your healthcare provider tells you to.  </item>
                                 <item>Cleanse the treated area before applying metronidazole gel. </item>
                                 <item>Apply and rub in a thin film of metronidazole gel 1 time a day to the affected area(s). </item>
                                 <item>You can apply cosmetics after applying metronidazole gel. </item>
                                 <item>Avoid contact of metronidazole gel with your eyes. </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> What are the possible side effects of Metronidazole gel</content>
                              <content styleCode="bold"> ?</content>
                              <br/>
                              <content styleCode="bold"> Metronidazole gel</content>
                              <content styleCode="bold">  may cause serious side effects, including:</content>
                              <br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold"> Peripheral neuropathy.</content>  Tingling, burning, pain or numbness in the hands or feet (peripheral neuropathy) have happened in people treated with metronidazole used on the skin. Tell your healthcare provider if you experience tingling, burning, pain or numbness in your hands or feet during treatment with metronidazole gel. </item>
                                 <item>
                                    <content styleCode="bold"> Skin reactions,</content>  including allergic reactions. Tell your healthcare provider if you develop any skin reactions, including rash, itching, redness, swelling, or blisters during treatment with metronidazole gel.  </item>
                                 <item>
                                    <content styleCode="bold"> Eye irritation.</content>  Tearing from eye irritation has happened in people treated with metronidazole used on the skin. Tell your healthcare provider if you experience tearing, redness or discomfort of the eyes during treatment with metronidazole gel.  </item>
                              </list>
                              <content styleCode="bold"> The most common side effects of Metronidazole gel</content>
                              <content styleCode="bold">  include: </content>
                              <br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>sore throat and nasal congestion </item>
                                 <item>upper respiratory tract infections </item>
                                 <item>headache </item>
                              </list>
 Tell your healthcare provider if you get any side effects during treatment with metronidazole gel.  <br/> These are not all of the possible side effects of metronidazole gel. <br/> Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.  <br/> You may also report side effects at 1-866-210-9797. <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> How should I store Metronidazole gel</content>
                              <content styleCode="bold"> ? </content>
                              <br/> • Store metronidazole gel at room temperature between 68°F to 77°F (20°C to 25°C). <br/>
                              <content styleCode="bold"> Keep Metronidazole gel</content>
                              <content styleCode="bold">  and all medicines out of the reach of children. </content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> General information about the safe and effective use of Metronidazole gel</content>
                              <content styleCode="bold"> . </content>
                              <br/> Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use metronidazole gel for a condition for which it was not prescribed. Do not give metronidazole gel to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about metronidazole gel that is written for health professionals. <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> What are the ingredients in Metronidazole gel</content>
                              <content styleCode="bold"> ? </content>
                              <br/>
                              <content styleCode="bold"> Active ingredient:</content>  metronidazole <br/>
                              <content styleCode="bold"> Inactive ingredients:</content>  betadex, edetate disodium, hydroxyethyl cellulose, methylparaben, niacinamide, phenoxyethanol, propylene glycol, propylparaben and purified water <br/> Manufactured by:<br/>
                              <content styleCode="bold"> Alembic Pharmaceuticals Limited</content>
                              <br/> (Derma Division),<br/> Karakhadi, Vadodara 391450, India.<br/> Mfg. License No.: G/25/2216<br/> For more information, call at 1-866-210-9797. <br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="ID96">This Patient information has been approved by the U.S. Food and Drug Administration                                        03/2025</paragraph>
               </text>
               <effectiveTime value="20250318"/>
            </section>
         </component>
         <component>
            <section ID="ID79">
               <id root="1ad9b56b-f9be-4c6f-bad3-fa7bfadbf10d"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph ID="ID80">
                     <content styleCode="bold">Metronidazole Gel USP, 1% </content>
                  </paragraph>
                  <paragraph>For Topical Use Only</paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC </content>46708-630-60</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">60 grams</content>
                  </paragraph>
                  <paragraph>For topical use only.</paragraph>
                  <paragraph>Not for oral, ophthalmic or intravaginal use.</paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Keep out of reach of children.</paragraph>
                  <paragraph>Usual dosage: Apply a thin film once a day to affected areas.  See prescribing information for complete instructions.</paragraph>
                  <paragraph>Each gram contains: 10 mg (1%) metronidazole USP, as active ingredient in a gel base consisting of betadex, edetate disodium, hydroxyethyl cellulose, methylparaben, niacinamide, phenoxyethanol, propylene glycol, propylparaben, and purified water.</paragraph>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Alembic Pharmaceuticals Limited</content>
                  </paragraph>
                  <paragraph>(Derma Division),</paragraph>
                  <paragraph>Karakhadi, Vadodara 391450, India.</paragraph>
                  <paragraph>Mfg. License No.: G/25/2216</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20250318"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ccb6c97f-34f9-4aeb-81ba-824a9b8a0ecd-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>carton label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ccb6c97f-34f9-4aeb-81ba-824a9b8a0ecd-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>